NasdaqCM:CLDXBiotechs
Weighing Celldex Therapeutics (CLDX) Valuation As Price-To-Book And DCF Send Mixed Signals
Celldex Therapeutics (CLDX) stock snapshot
Celldex Therapeutics (CLDX) has drawn fresh attention after recent trading moves, with the stock showing a 6.3% gain over the past month and a 40.2% return in the past 3 months.
See our latest analysis for Celldex Therapeutics.
Despite a 3.1% one day share price pullback to US$33.32, Celldex’s recent 30 day share price return of 6.3% and 90 day share price return of 40.2% point to building momentum. The 1 year total shareholder return of 70.7% shows...